Country: Armenia
Language: English
Source: Դեղերի և բժշկական տեխնոլոգիաների փորձագիտական կենտրոնի գործունեության Հայաստանի Հանրապետությունում
obinutuzumab
F. Hoffmann-La Roche Ltd. 4303 Kaiseraugst- batch releaser
L01XC15
obinutuzumab
1000mg/40ml
concentrate for solution for infusion
(1) glass vial 40ml
Prescription
Registered
2017-09-26
GAZYVA ® Obinutuzumab 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Antineoplastic agent, monoclonal antibody. ATC code: L01XC15 obinutuzumab. 1.2 TYPE OF DOSAGE FORM Concentrate for solution for infusion. 1.3 ROUTE OF ADMINISTRATION Intravenous infusion. 1.4 STERILE / RADIOACTIVE STATEMENT Sterile product. 1.5 QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient: _ obinutuzumab. Gazyva is a clear, colorless to slightly brownish liquid supplied as a single 1000 mg dose in a sterile, preservative-free, non- pyrogenic 50 ml glass vial containing 40 ml of liquid concentrate (25 mg/ml). _Excipients:_ L-histidine/L-histidine hydrochloride, trehalose, poloxamer 188, and water for injection. 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. 2.2 DOSAGE AND ADMINISTRATION GENERAL Substitution of Gazyva with any other biological medicinal product requires the consent of the prescribing physician. Gazyva should be administered as an intravenous infusion through a dedicated line in an environment where full resuscitation facilities are immediately available and under the close supervision of an experienced physician. Gazyva infusions should not be administered as an intravenous push or bolus. Isotonic 0.9% sodium chloride solution should be used as the infusion vehicle (see _ 4.2 Special Instructions for Use, Handling _ _and Disposal_ ). _PROPHYLAXIS AND PREMEDICATION FOR TUMOR LYSIS SYNDROME _ _(TLS)_ Patients with a high tumor burden and/or a high circulating lymphocyte count (> 25 x 10 9 /l) and/or renal impairment (CrCl <70 ml/min) are considered at risk of TLS and should receive prophylaxis. Prophylaxis should consist of adequate hydration and administration of uricostatics (e.g. allopurinol) or suitable alternative such as a urate oxidase (e.g. rasburicase) prior to start of Gazyva infusion as per standard practice (see _2.4 Read the complete document
August 2015 Summary of Product Characteristics Ro 5072759 Gazyva August 2015 Product Information FE/English 1 GAZYVA ® Obinutuzumab 1. DESCRIPTION 1.1 THERAPEUTIC / PHARMACOLOGIC CLASS OF DRUG Antineoplastic agent, monoclonal antibody. ATC code: L01XC15 obinutuzumab. 1.2 TYPE OF DOSAGE FORM Concentrate for solution for infusion. 1.3 ROUTE OF ADMINISTRATION Intravenous infusion. 1.4 STERILE / RADIOACTIVE STATEMENT Sterile product. 1.5 QUALITATIVE AND QUANTITATIVE COMPOSITION _Active ingredient: _obinutuzumab. Gazyva is a clear, colorless to slightly brownish liquid supplied as a single 1000 mg dose in a sterile, preservative-free, non-pyrogenic 50 ml glass vial containing 40 ml of liquid concentrate (25 mg/ml). _Excipients:_ L-histidine/L-histidine hydrochloride, trehalose, poloxamer 188, and water for injection. 2. CLINICAL PARTICULARS 2.1 THERAPEUTIC INDICATION CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) Gazyva in combination with chlorambucil is indicated for the treatment of patients with previously untreated chronic lymphocytic leukemia. 2.2 DOSAGE AND ADMINISTRATION GENERAL Substitution of Gazyva with any other biological medicinal product requires the consent of the prescribing physician. Gazyva should be administered as an intravenous infusion through a dedicated line in an environment where full resuscitation facilities are immediately available and under the close supervision of an experienced physician. Gazyva infusions should not be administered as an intravenous push or bolus. Isotonic 0.9% sodium chloride solution should be used as the infusion vehicle (see_ 4.2 Special Instructions for Use, Handling and _ _Disposal_). August 2015 Summary of Product Characteristics Ro 5072759 Gazyva August 2015 Product Information FE/English 2 _PROPHYLAXIS AND PREMEDICATION FOR TUMOR LYSIS SYNDROME (TLS) _ Patients with a high tumor burden and/or a high circulating lymphocyte count (> 25 x 10 9 /l) and/or renal impairment (CrCl <70 ml/min) are considered at risk of TLS and should receive prophylaxis. Prophylaxis should consi Read the complete document